Small-molecule disaggregators and inhibitors
The company develops these molecules to target misfolded proteins described as previously undruggable in neurodegenerative diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
Adrx is a preclinical biotechnology company developing small-molecule approaches targeting misfolded proteins in neurodegenerative diseases.
Its pipeline includes programs focused on tau, TDP-43, and alpha-synuclein.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company develops these molecules to target misfolded proteins described as previously undruggable in neurodegenerative diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.